



Novo Seeds

NOVO

novo nordisk fonden

SOWING THE SEEDS OF TOMORROW'S BIOTECH SUCCESS

NOVO SEEDS PROVIDES FUNDING, KNOWLEDGE AND NETWORK FOR NORDIC PROJECTS AND COMPANIES THAT DEVELOP UNIQUE LIFE SCIENCE SOLUTIONS FOR THE FUTURE.

Launched in 2007 by the Novo Nordisk Foundation and Novo A/S, Novo Seeds invests in early stage life science research. Through our investment programmes, we contribute to a dynamic Nordic life science environment.

HELPING SEEDS GROW

The pre-seed and seed investment programmes aim to develop the scientific and commercial potential of Nordic life science research.


Pre-seed grants are given to explore the commercial potential of research findings and ideas to development of new medical treatments, disease prevention and diagnostic methods, as well as biotechnology.

We administer the pre-seed programme on behalf of the Novo Nordisk Foundation and award grants to researchers at universities or medical staff at hospitals.

Our seed investment programme supports more advanced research projects that show significant

commercial potential that can be matured to attract venture financing. Unlike the pre-seed grant, our seed investment operates on commercial terms. Our support is given to projects and companies in exchange for ownership or other rights to the company or project in question.

To learn more about the types of projects we've supported, check the insert. It also tells you which projects have moved successfully from pre-seed to seed funding.



OUR PROGRAMMES

PRE-SEED GRANTS:


- Grant funding, administered on behalf of the Novo Nordisk Foundation
- Provide support to applied life science research with commercial potential*
- No claim for equity
- Applicants: Nordic researchers and doctors

SEED INVESTMENTS:

- Equity investments, administered on behalf of Novo A/S
- Designed to develop the company's commercial potential
- Claim for equity
- Applicants: Nordic researchers, entrepreneurs and early stage life science companies


* If you've managed to secure other funding for your project, you can still apply for a pre-seed grant. If you've received investor capital, the pre-seed grant is no longer available to you.

OUR STRUCTURE





FROM
GREAT
IDEA TO
**COMMERCIAL
SUCCESS**



WHAT IS THE DIFFERENCE BETWEEN A BASIC RESEARCH GRANT AND A PRE-SEED GRANT?



Basic research grants and pre-seed grants support different research activities. Before you apply, take a look at the lists to see if your project qualifies for a basic research grant or pre-seed funding.

BASIC RESEARCH GRANTS:

- Discovery-driven to obtain more knowledge
- Commercial potential not in focus
- Publication of findings is typically a primary goal
- The application deadline is fixed


PRE-SEED GRANTS:

- Application-driven – with a goal of developing a particular product, therapy or technology
- Testing of commercial potential and development of business plan
- IP to be secured before publication
- The application deadline is flexible



THE INNOVATION CHAIN

- Novo Nordisk Foundation supports basic and applied science
- Novo A/S operates from seed funding to venture financing



GOT A GREAT IDEA? TELL US ABOUT IT!

The novo seeds life science team is dedicated to finding and supporting promising life science projects that can lead to new and better healthcare treatments and technologies. By combining your skills and commitment with our commercial experience, we believe we can drive your idea to market.

Nordic and international biotech industry to provide project owners with the expert advice they need within their given field. Being actively involved in all our investments, we ensure that each project has the best conditions for success. Hopefully, this will turn ideas into solutions that are ready to bring to market.

a PowerPoint presentation or a dummy of the product itself, it's entirely up to you. Your presentation needs to communicate the uniqueness of your idea – and convince us of its market potential. We're also very interested in knowing more about the technology behind your innovation, current and future stages of research, and the professional expertise of your team.

ACTIVE PARTNERSHIP

Capital is crucial to the successful growth of a new project. But it takes more than money to transform pioneering ideas into viable solutions. Nurture and knowhow are equally important. At Novo Seeds, we use our commercial expertise to provide projects and companies with the managerial and strategic support they need to steer through critical start-up phases. We also draw on our network of associates from the

WE NEED NEW TECHNOLOGIES AND TREATMENTS TO MEET THE CHALLENGES OF A CHANGING WORLD. NOVO SEEDS IS THERE TO HELP REALISE YOUR IDEA.

HOW DO I APPLY?

We receive many enquiries from potential applicants who wish to know how to draft their application. Except for the exploratory pre-seed grant program there is no set format. You can submit a business plan,

GREAT IDEAS CONQUER COMPETITION

The competition for funding in life science is tough.

Every year, our team evaluates

over a hundred new projects, and only a few of these make it through the selection process. But your project might just be among the lucky few. So why not send us your project for review?

We look forward to hearing from you.



THE SELECTION PROCESS

We carefully assess all incoming applications, balancing the scientific and commercial potential of each project.

The steps in the selection process involve:

- Screening of all incoming projects
- Review and dialogue with project owners and the Novo Seeds team
- Final review and approval of the most qualified projects and companies by the Novo Seeds Investment Committee
- Allocation of funding



SUBMISSION OF PROJECTS




SCREENING OF PROJECTS



REVIEW AND DIALOGUE



PRE-SEED GRANT OR SEED INVESTMENT



MEET THE NOVO SEEDS TEAM

STEPHAN CHRISTGAU, INVESTMENT DIRECTOR



joined Novo A/S in 2007 from Osteologix Inc. where he served as Chief Operating Officer. Stephan holds an MSc from the Technical University of Denmark (DTU) and a PhD from the University of California (UCFS) and has held various positions in the Danish pharma and biotech industry – at Novo Nordisk A/S,

Osteometer Biotech A/S, and Nordic Bioscience A/S. Stephan serves on several boards and is actively involved in various entrepreneurship initiatives.

SØREN MØLLER, MANAGING INVESTMENT DIRECTOR



joined Novo A/S in 2011 from a position as head of Bioinformatics and Genomics division at Novozymes A/S. Prior to that, Søren served as VP R&D and Chief Scientific Officer at Exiqon A/S, where he played a leading role in building the company's life science and diagnostic business. Søren holds a PhD from the Technical University

of Denmark (DTU) and a Post Doc from Stanford University. Søren is an active member of several boards.

HENRIJETTE RICHTER, INVESTMENT DIRECTOR



joined Novo A/S in 2007 from SunStone Capital, where she served as Director of Scientific Analysis responsible for screening and selection of new investment opportunities. Henrijetta has an industrial PhD from Novo Nordisk A/S and did her Postdoctoral Fellowship at Massachusetts Institute of Technology


(MIT) as a Postdoctoral Fellow. She also holds a CBA from Copenhagen Business School (CBS). Henrijetta serves on several boards.

BERIT MIKKELSEN, COORDINATOR



joined Novo A/S in 2009. She has a technical background and holds a commercial degree from Copenhagen Business School (CBS) and is actively involved in various innovation and entrepreneurship initiatives.

BOBBY SONI, PRINCIPAL



joined Novo A/S in 2009 from LEO Pharma, where he worked as Discovery Licensing Manager responsible for pre-clinical stage licensing and outsourcing. Earlier in his career, he headed scientific projects at the biotech company Maxygen ApS. Bobby has a BSc in Biochemistry from University of Rochester and a PhD in

Biology from University of Virginia and Imperial College, London.


Bobby serves on several boards.

SØREN CARLSEN, MANAGING PARTNER



has worked in the Novo Group for more than 25 years. He headed the start-up of Novozymes Biotech Inc. in the US and served as Chief Scientific Officer at Novo Nordisk Enzyme Business, now known as Novozymes A/S. Today, he heads Novo Ventures and Novo Seeds.

He also serves on several boards and is Chairman of the Association of Biotechnology Industries in Denmark.



Novo A/S

Tuborghavnevej 19
DK-2900 Hellerup
Danmark

Tel +45 3527 6500
Fax +45 3527 6510
seedscontact@novo.dk
www.novo.dk



PRE-SEED GRANTS



SMALL MOLECULES

GALECTO

develops new treatments for inflammation and cancer, based on galectin inhibitors.

COPA

develops anti-bacterials based on structural insight into CopA, a novel bacterial target.

BIOFILM

develops novel biofilm inhibitors as adjunctive anti-bacterial therapy for resistant infections.

PCOVERY

focuses on structure based drug development against membrane protein drug targets with a broad portfolio of innovative technologies, drug targets and chemical products.



BIOLOGICS

PLUVIA

works to develop small molecule chaperones for the treatment of rare genetic diseases, such as Phenylketonuria.

PROREC

investigates a new cancer treatment that targets prolactinomas in the pituitary gland.

CYTOGUIDE

is developing macrophage targeted drugs for the treatment of inflammation and cancer.

ORPHAZYME

develops new therapeutic strategies for the treatment of lysosomal storage diseases.



VACCINES

NOVVAC

is refining its unique bioinformatics platform, VacFinder™, that identifies superior vaccine antigens.

PREGMALVAC

works to develop a vaccine against pregnancy-associated malaria.

INVACC

Possesses a proprietary platform for enhancing the potency of DNA-vaccines.

SIMPLEXIA

is working on a novel vaccine against genital herpes caused by herpes simplex virus type 2 (HSV-2).



DEVICES

NANOVI

develops x-ray dense nanoparticles to directly mark tumours. With its NanoTrap™ technology, the company works to improve the precision of radiation delivery.



DIAGNOSTICS


NO CURRENT PROJECTS



INDUSTRIAL BIOSOLUTIONS

NO CURRENT PROJECTS

SEED INVESTMENTS

Adenium Biotech 

ADENIUM BIOTECH develops broad-spectrum antibiotics for the treatment of resistant anti-bacterial infections.
www.adeniumbiotech.com



AROS PHARMA focuses on the development of new macrolide antibiotics to treat severe respiratory infections. www.arospharma.com

CONCIT PHARMA



CONCIT PHARMA identifies and develops innovative drug combinations for treatments of movement disorders and pain.
www.concitolpharma.com

cytoguide

CYTOGUIDE develops combined drugs that target receptors on cells in pathological tissues. The combinatory drugs are used for the treatment of diseases where macrophages play a key role.
www.cytoguide.dk

C10 | PHARMA

C10 PHARMA focuses on the development of new macrolide antibiotics to treat severe respiratory infections. www.c10pharma.com

 Epi Therapeutics

EPITHERAPEUTICS specialises in the development of innovative cancer drugs to regulate epigenetic mechanisms. The company's lead programme targets prostate cancer.
www.epitherapeutics.dk

INAGEN

INAGEN develops new anti-viral treatments. The company's primary drug candidate targets Cytomegalovirus (CMV), a major problem for immune-suppressed patients. www.inagen.com

PCOVERY 

PCOVERY focuses on structure-based drug development against membrane protein drug targets with a broad portfolio of innovative technologies, drug targets and chemical products.
www.pcovery.com

THROMBOLOGIC

THROMBOLOGIC is developing a new therapy for the treatment of sepsis and multiple organ failure in critically ill patients. Their first clinical study was initiated in 2010.
www.thrombologic.com